Navigation Links
Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately
Date:11/4/2010

th or without Proposition 19, the Company's focus has been and will remain on submitting our initial Investigative New Drug Applications to the FDA so we can begin formally testing our formulations. Dr. Melamede and I have long advocated the complete legalization of cannabis for adults. However, the company's business model does not depend on any changes in the laws. In fact, we expect that there will be an increased demand for our products and the need for professional standards becomes clear to the patients, the public, and even the politicians." 

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undert
'/>"/>

SOURCE Cannabis Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Is GMO Food and Organic Food an Either/Or Proposition?
2. Boston Scientific Announces Court Decision
3. Vermillion Announces Receipt of NASDAQ Panel Decision
4. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
7. Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
8. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
9. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
10. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
11. DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Eli Lilly and Company (NYSE: LLY ) ... therapies, reflecting Lilly,s diverse oncology pipeline, during the American ... April 18-22 in Philadelphia , Pa.  ... the theme of this year,s AACR meeting and one ... portfolio of therapies that accelerate the pace and progress ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/18/2015)... 18, 2015 Aurigene and ... will be presenting data at the poster sessions ... Cancer Research Annual Meeting (April 18-22 in ... (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene ... (NAMPT) small molecule inhibitors program, which is currently ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
Breaking Biology Technology:Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... 7 Endocare, Inc. (Nasdaq: ENDO ) ... have entered into a settlement agreement stipulating to termination ... Galil Medical pursuant to which Endocare would have acquired ... in Delaware Chancery Court. , , ...
... Covance Inc. today ... company as vice president and chief scientific officer of ... industry experience, including bioanalytical research, translational research, and talent ... development strategy for Covance,s bioanalytical services. , ...
... advanced energy research , , MONTREAL, July 7 ... technology company, today announced that it will jointly form ... Edmonton and the Alberta Energy Research Institute (AERI). , ... demonstration of novel catalytic conversion processes to produce advanced ...
Cached Biology Technology:Endocare and Galil Medical Announce Settlement of Litigation 2Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 3
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... video footage from the forests of Thailand have given ... paying off, according to the Wildlife Conservation Society. ... across Thailand,s Western Forest Complex over the last yearhas ... of tigers, Asian elephants, gaurs, sun bears, and many ...
... whether a person has Alzheimer,s disease before symptoms ... University of Gothenburg, Sweden, have studied biomarkers that ... term, the possibility of effective new treatments. ... forms clumps between the nerve cells of the ...
... Ga. It,s rubbed on the skin to reduce signs ... scientists now have the first evidence of one of vitamin ... foods helps repair tears in the plasma membranes that protect ... Georgia Health Sciences University researchers report in the journal ...
Cached Biology News:Candid video clips from Thailand show anti-poaching efforts saving wildlife 2Scientists identify an innate function of vitamin E 2
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
Biology Products: